ASCO GI 2023 | How can be IO for liver cancer be utilized in the transplant setting?

Gonzalo Sapisochin, MD, Toronto General Hospital, Toronto, CA, discusses the future of immunotherapy (IO) in liver transplantation for patients with liver cancer. Molecular testing has enabled the identification of patients who will benefit the most from transplantation. Further research is required to elucidate the effects of IO administered before transplantation, and if it affects immunosuppression. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.